Novartis Ordered to Pull Anti-arthritis Drug from Philippines

by Medindia Content Team on  January 18, 2008 at 6:50 PM Drug News   - G J E 4
Novartis Ordered to Pull Anti-arthritis Drug from Philippines
Philippine health regulators on Friday ordered Swiss pharmaceutical giant Novartis to pull the painkiller Lumiracoxib from the market amid fears the drug could cause liver damage.

The health department's Bureau of Food and Drugs ordered Novartis Healthcare Philippines Inc. to "immediately initiate a product recall and cease and desist from further importing, distributing, or selling Lumiracoxib (Prexige)" tablets.

A bureau advisory said it has "determined that the risks of Lumiracoxib-containing medicines are greater than their benefits," citing "reports of cases from abroad concerning potential serious liver-related side effects."

The anti-inflammatory drug is used to treat symptoms of osteoarthritis and dysmenorrhia as well as in dental and orthopaedic surgery, the bureau said.

"Patients who are using Lumiracoxib (Prexige) are advised to stop taking the drug and to immediately consult their physicians for information regarding their alternative treatments," the advisory added.

A spokeswoman for bureau director Leticia Gutierrez told AFP: "Novartis is in the process of recalling the drug from its distribution outlets."

She added that the bureau had no data on the number of people using the drug in the country and there were no reports of any patients showing the same symptoms as those reported in other countries.

Novartis announced in November that Prexige had been suspended from sale and marketing in Britain and Germany amid fears it can cause liver damage.

Austria, Australia and Canada have taken similar steps, while Prexige has not been approved for sale in the United States.

Source: AFP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like